Thanks to a new skin cancer screening technology developed by Latvian researchers, clinicians across the EU may soon have access to a portable device that can detect melanoma without a biopsy.
2024
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma
The phase 3 KeyVibe-010 trial (NCT05665595) evaluating the combination of adjuvant vibostolimab (MK-7684A) and pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected high-risk stage IIB, IIC, III, and IV melanoma has been discontinued.
Disparities in Melanoma Outcomes Among Black Patients
Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients, according to a recent study published by Steadman et al in the Journal of Surgical Oncology.
Asian American and Pacific Islander Patients Face Increased Odds of Melanoma Treatment Delay
Researchers say addressing socioeconomic differences may be the key to addressing this disparity.